EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Clariane SE (0OPS) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Clariane SE €8.35, price €3.21, upside +160.0%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · GB · ISIN FR0010386334

CS Some data Sep 24, 2026

Clariane SE

0OPS · LSE

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value €8.35 · Strongly undervalued (+160.0%)
!Quality 51/100
!Mixed Growth (revenue 5y +8.4 %/yr)
!Thin margins · 0.0% net margin (TTM)
✓Moderate debt · generates free cash flow
!Narrow moat 30/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range €2.37 to €16.94

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€20.11 €0.8612 Fair Value €8.35 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range €0.8612 – €20.11 · fair‑value band €2.37 – €16.94 · the €3.21 price screens below the €8.35 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Clariane SE provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom. It operates long-term care and short stay nursing homes.

Show more

Clariane SE provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom. It operates long-term care and short stay nursing homes. The company also provides inpatient and outpatient services, full-time hospitalization, day hospitalization, and outpatient care, and operates post-acute and rehabilitation care clinics, mental healthcare clinics, and medicine-surgery-obstetrics facilities. In addition, it offers medicalized nursing homes and alternative living solutions, such as shared houses, assisted living, and domiciliary care, as well as outpatient consultations and diagnostics, and social care services. The company was formerly known as Korian and changed its name to Clariane SE in June 2023. Clariane SE was founded in 2001 and is headquartered in Paris, France.

Stock analysis

Clariane SE (0OPS) currently trades at €3.21, while our model-based Fair Value estimate is €8.35, implying the stock looks roughly 61.5% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of €8.88 per share, and 11 of the 13 models we run sit above the €3.21 price.

Bear case: the Dividend Discount group reads lowest at €2.81, and 2 of the 13 models stay below the price. Evidence for this calculation is medium.

Scenario range: €2.37 (bear) to €16.94 (bull), the price of €3.21 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Clariane SE reported revenue of €5.0B in FY2023 versus €3.6B in FY2019, a compound +8.4%/yr. Reported net income was −€92.4M in FY2023.

Key figures

Market cap €1.2B · P/E ratio 0.2 · P/S ratio 0.22 · EPS (TTM) €0.7320 · Net margin −1.9% · Return on equity 0.2% · Return on assets (EBIT) 2.0% · Operating margin 13.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 160%, 0OPS screens cheaper than that median.

Fair Value models

Bear €2.37 Fair Value €8.35 Bull €16.94
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF €2.62 €8.88 €17.99 74
Growth DCF €2.54 €8.22 €16.07 73
5Y EBITDA Exit €15.98 €36.40 €61.60 72
All 15 models by family
DCF Models
FCF DCF €2.62 €8.88 €17.99 74
5Y Revenue Exit €0.9400 €6.53 €13.83 65
5Y EBITDA Exit €15.98 €36.40 €61.60 72
10Y Revenue Exit €1.24 €6.38 €13.67 60
10Y EBITDA Exit €10.46 €25.96 €48.90 64
Earnings-Based
EPV n/a n/a €0.1100 68
Dividend Discount
Gordon GGM €1.71 €3.07 €4.23 68
DDM Multi-Stage €1.71 €2.81 €3.28 67
Multiples
EV/EBIT €3.57 €7.50 €11.42 62
EV/EBITDA €27.83 €39.84 €51.85 67
EV/Revenue €0.2000 €3.80 €7.40 46
Asset-Based
NCAV (Graham) €5.99 €8.03 €11.98 54
Growth DCF
Growth DCF €2.54 €8.22 €16.07 73
Rev-Margin DCF €0.9400 €6.52 €13.44 65
Economic Profit
ROIC Compounder n/a n/a €0.1100 68

Open the full fair value analysis →

Notify me when 0OPS reaches fair value

Put 0OPS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 48 · Market factors (momentum, volatility) 29

Profitability 13
Margins and returns on capital today
Quality Growth 44
Are margins and returns improving?
Cashflow 66
Earnings quality: real cash, not paper profit
Fin. Strength 19
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 64
Calm price path (market factor)
Momentum 22
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 91
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.1% (2018) → 5.5% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
not computed

Watch 0OPS, get fair value alerts →

Compare Clariane SE with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $431.63 $597.97 +39%
Fresenius SE FRE €43.64 €34.49 −21%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $257.93 $274.35 +6%
IHH Healthcare Berhad, an investment holding company, 5225 8.03 MYR 4.87 MYR −39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.27 $45.84 +106%
DaVita Inc DVA $178.07 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Clariane SE · Fair Value
€8.35 +62%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Clariane SE Fair Value". https://www.fairvalue-calculator.com/stock/0OPS

Frequently asked questions

Is Clariane SE (0OPS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €8.35 versus a price of €3.21, about +160% upside (undervalued).
What is the fair value of 0OPS?
Our model-based fair value for Clariane SE is €8.35 (as of Sep 24, 2026), built from audited fundamentals. The current price: €3.21.
What is the quality score of 0OPS?
Clariane SE has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Clariane SE (0OPS)?
Our model-based price target is the fair value of €8.35 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario €2.37, optimistic scenario €16.94. It is a calculation from audited fundamentals, not an analyst target.
What is the Clariane SE stock forecast for 2026?
Our models put fair value at €8.35, about +160% upside versus a price of €3.21 (undervalued). Cautious scenario €2.37, optimistic scenario €16.94. The calculation is refreshed regularly with new filings.
What is the revenue of Clariane SE (0OPS)?
Clariane SE reported trailing-twelve-month revenue of about €5.3B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Clariane SE (0OPS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Clariane SE it is €8.35 per share (as of Sep 24, 2026), against a price of €3.21. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Clariane SE stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0OPS trades below its calculated fair value: price €3.21, fair value €8.35, a gap of about +160% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0OPS?
No. The price is what the market pays today (€3.21); the fair value is what the company's own numbers justify (€8.35). For Clariane SE the two are €5.14 per share apart. That gap is exactly why we show both numbers side by side.
How much is Clariane SE worth?
The market values Clariane SE at about €1.2B (market capitalisation, as of Sep 24, 2026). Per share that is €3.21; our models calculate a fair value of €8.35 per share.
What do the bullish and bearish scenarios say about 0OPS?
Our models span a range for Clariane SE: cautious scenario €2.37, base €8.35, optimistic €16.94 per share (as of Sep 24, 2026, price €3.21). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0OPS from its 52-week high?
Clariane SE trades at €3.21, about 32% below its 52-week high of €4.73 and at the low of €3.21 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €8.35 is for.
Which stocks are comparable to Clariane SE?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Clariane SE stock attractive at the current price?
The data as of Sep 24, 2026: price €3.21, calculated fair value €8.35 (+160%), Quality Score 51/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0OPS calculated?
We run Clariane SE through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €8.35, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Clariane SE currently trades 62 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Clariane SE (0OPS)?
The closing price on Oct 2, 2026 was €3.21. Our model-based fair value is €8.35, about +160% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Clariane SE right now?
The model range is unusually wide (€2.37 to €16.94). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Clariane SE (0OPS) come from?
Earnings per share at Clariane SE grew −3.6 % a year from 2012 to 2023. Broken into its drivers: revenue per share +1.4 %, EBIT margin −4.4 %, tax rate +5.3 %, residual (interest, one-offs) −5.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Clariane SE

How large is the market capitalisation of Clariane SE (0OPS)?
The market capitalisation of Clariane SE is €1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Clariane SE (0OPS)?
The price-to-earnings ratio of Clariane SE is 0.2 (as of Jul 28, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Clariane SE (0OPS)?
The price-to-sales ratio of Clariane SE is 0.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Clariane SE (0OPS)?
Earnings per share at Clariane SE are €0.7320 (price ÷ EPS = P/E 0.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Clariane SE (0OPS)?
The net margin of Clariane SE is −1.9% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Clariane SE (0OPS)?
The return on equity (ROE) of Clariane SE is 0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Clariane SE (0OPS)?
On an EBIT basis the return on assets of Clariane SE is 2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Clariane SE (0OPS)?
The operating margin of Clariane SE is 13.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at Clariane SE (0OPS)?
Earnings per share at Clariane SE are growing −63.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Clariane SE (0OPS) generate?
The free cash flow of Clariane SE is €320M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Clariane SE (0OPS) carry?
The net debt of Clariane SE is €7.5B (fiscal year 2023, ≈ 23.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.